Elran Haber, CEO of Therapix Biosciences, which is developing intranasal cannabinoid-based drugs, will step down “to pursue other professional opportunities” after the company concludes its search for “a permanent, US based Chief Executive Officer,” the company said.
Over the past year, the Israeli company has licensed both an intranasal cannabinoid formulation and intranasal delivery technology from Yissum Research Development Company, which is Hebrew University’s technology transfer company.
Therapix Chairman of the Board Ascher Shmulewitz said, “On behalf of the Therapix board of directors, I would like to thank Dr. Haber for his extraordinary service to our company. Therapix made considerable progress under his leadership, including a successful US initial public offering, and significant advancement in the company’s clinical development programs.
Haber commented, “It has been a sincere pleasure to lead Therapix and I am proud of all we accomplished. I am thankful for the opportunity to have worked with a world-class team of professionals. I believe that the company has reached the point at which it will benefit from US-based leadership.”
Read the Therapix press release.
